Aerodose Insulin Inhaler Efficiency vs. Competition

Aerogen Henry et al Type 2 21%

2001 n=24

Sponsor Author/Date Patients Relative BA

Brunner et al Type 1 8%

Aradigm 2001

Novo Nordisk Kipnes et al Type 1 16%
2000 n=18

Inhale Skyler et al Type 1 5%

Pfizer/Aventis 2001 n=73

Previous slide

Next slide

Back to first slide

View graphic version